Avirmax Biopharma, based in Hayward, California, announced a significant milestone on February 3, 2025, with the completion of the first cohort enrollment in the Phase I/IIa clinical trial of ABI-110, a gene therapy targeting Wet Age-related Macular Degeneration (AMD) and Polypoidal Choroidal Vasculopathy (PCV).

The clinical trial aims to address the underlying genetic causes of Wet AMD and PCV, potentially offering a more durable and effective treatment solution compared to current therapies.

ABI-110 is designed to provide an ultra-long acting treatment option for these conditions, which currently require patients to undergo frequent injections for temporary relief.

This innovative therapy utilizes Avirmax's proprietary engineered capsid, AAV.N54, which is specifically designed for the efficient delivery of therapeutic transgenes to the macular retina via intravitreal injection.

According to Principal Investigator Roger A. Goldberg, M.D., M.B.A., no serious adverse events or dose-limiting toxicities were reported among the three subjects in Cohort 1.

Avirmax Biopharma specializes in next-generation gene therapies aimed at improving patient outcomes and preserving vision for various retinal diseases.